R&D Trends

Aesica, University of Nottingham to develop novel amide chemical synthesis technique

Wednesday, May 8, 2013 11:36 AM

Aesica, a global contract manufacturing organization, has formed a partnership with the University of Nottingham for the commercial development of alternative methods in amide bond synthesis.

More... »

Recipharm, Synthonics to promote novel drug delivery technology

Wednesday, May 8, 2013 09:40 AM

Recipharm Pharmaceutical, a Swedish contract development and manufacturing organization (CDMO), and Synthonics, a specialty pharmaceutical company based in Blacksburg, Va., have formed a Joint Promotion Agreement.

More... »

Concert Pharmaceuticals, Celgene to develop deuterium-modified compounds

Tuesday, May 7, 2013 08:00 AM

Concert Pharmaceuticals, a clinical stage biotechnology company, has entered into a strategic collaboration with Celgene, a Summit, N.J.-based integrated global biopharmaceutical company, directed towards deuterium-modified compounds targeting cancer and inflammation. The collaboration will initially focus on one program, but has the potential to encompass multiple targets.

More... »

Ambrx, BMS collaborate on next-gen antibody drug conjugates

Monday, May 6, 2013 10:09 AM

Ambrx, a clinical stage biopharmaceutical company, entered into a collaboration agreement with Bristol-Myers Squibb for the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chemistry technology.

More... »

Soligenix, Intrexon pursue melioidosis therapy through exclusive collaboration

Friday, May 3, 2013 10:48 AM

Soligenix, a clinical stage biopharmaceutical company focused on inflammatory diseases and biodefense countermeasures, will jointly develop a treatment for melioidosis through a worldwide exclusive collaboration with Intrexon, a synthetic biology company that utilizes its proprietary technologies to provide control over cellular function.

More... »

Abide Therapeutics, Merck to develop novel therapies for T2D, metabolic diseases

Friday, May 3, 2013 10:19 AM

Abide Therapeutics, a biopharmaceutical company pioneering innovative approaches to selectively target a group of enzymes known as serine hydrolases, has entered into a collaboration agreement with Merck, to discover, develop and commercialize small-molecule therapies directed against three novel targets to treat metabolic diseases with a focus on type 2 diabetes.

More... »

GSK, Impax Pharmaceuticals terminate collaboration on IPX066

Monday, April 29, 2013 02:25 PM

Impax Pharmaceuticals, the brand products division of Impax Laboratories, and GlaxoSmithKline (GSK) are terminating their collaboration for the development and commercialization of IPX066 outside the U.S. and Taiwan.

More... »

Esperion Therapeutics completes $33M financing to advance LDL-C lowering therapy

Friday, April 26, 2013 01:41 PM

Esperion Therapeutics, a clinical stage biopharmaceutical company focused on oral low-density lipoprotein cholesterol (LDL-C) lowering therapies for hypercholesterolemia and other cardiometabolic disorders, has completed a $33 million preferred stock financing led by new investor Longitude Capital.

More... »

CardioDx, Core Diagnostics India ink Corus CAD marketing agreement

Friday, April 26, 2013 12:04 PM

CardioDx, a developer of cardiovascular genomic diagnostics, has signed an agreement granting Core Diagnostics India the exclusive right to market and sell its Corus CAD diagnostic test in India.

More... »

High school junior Natalie Ng wins International BioGENEius Challenge

Friday, April 26, 2013 11:42 AM

Natalie Ng, a junior at Monta Vista High School in Cupertino, Calif., won the International BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research in biotechnology. Ng’s research in breast cancer and biomarkers helped her stand out from the 13 other finalists from across the U.S., Canada and Australia competing for the Challenge's top prize, a $7,500 cash award.

More... »